Effects of Dolutegravir on HIV treatment outcomes and health risks in South Africa.
Official title: Impact of Dolutegravir on Viral Suppression, Retention, and Risk of Non-Communicable Diseases among Persons Living with HIV in South Africa.
Funded at Boston University Medical Campus · NIH-10932563 · Data updated 2026-11-12
This study is looking at how the HIV medication dolutegravir helps people in South Africa stay healthy and manage their condition, especially in terms of keeping the virus under control and staying in regular care, while also checking for any long-term health issues that might come up.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $48,974 |
| NIH project number | 1F31AI179292-01A1 |
| Project ID | NIH-10932563 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV in South Africa who are receiving or have received treatment with dolutegravir.
✕Less likely to help
Patients who are not living with HIV or those who are not on a dolutegravir-based treatment regimen may not benefit from this research.
What this research studies
This research investigates how the antiretroviral drug dolutegravir affects the health outcomes of individuals living with HIV in South Africa, particularly focusing on viral suppression and retention in care. It aims to understand the long-term implications of dolutegravir treatment, especially concerning the risk of developing non-communicable diseases. By analyzing data from patients who have started treatment with dolutegravir, the study seeks to provide insights into the effectiveness of this medication compared to previous treatments. The research will utilize advanced epidemiological methods to assess these outcomes over time.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for HIV patients, enhancing their overall health and reducing the risk of additional diseases.
How similar studies have gone: Previous research has shown promising results regarding the effectiveness of dolutegravir, but this specific investigation into its long-term health impacts is novel.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Zheng, Amy — Boston University Medical Campus
- Study coordinator: Zheng, Amy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.